AS 1409
Alternative Names: Antibody-cytokine fusion drug (AS1409); AS-1409; BC1-IL-12; hBC1-hIL-12; huBC1/IL-12 fusion protein; huBC1/IL12 fusion drug; Tumour-targeting antibody BC1/IL-12 fusion drugLatest Information Update: 19 Jul 2012
At a glance
- Originator Antisoma; EMD Lexigen
- Developer Antisoma
- Class Antibodies; Antineoplastics; Interleukins; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interferon gamma stimulants; Natural killer cell stimulants; Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Malignant melanoma; Renal cancer
Most Recent Events
- 11 Jan 2012 Discontinued - Phase-I for Malignant melanoma in New Zealand (IV)
- 11 Jan 2012 Discontinued - Phase-I for Malignant melanoma in United Kingdom (IV)
- 11 Jan 2012 Discontinued - Phase-I for Renal cancer in New Zealand (IV)